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Abstract
Objectives: To report the results of health economic analyses comparing two treatment approaches for
chronic low back pain (CLBP).
Design: Observational prospective cohort study comparing effectiveness and cost-effectiveness of CLBP care
provided at an integrative care clinic with that provided in other clinics within the same hospital. CLBP-related
medical utilization, function, quality of life, and days of work incapacity were self-reported at baseline, 3, 6,
and 12 months.
Settings/Location: Osher Clinical Center (OCC) based at a tertiary academic hospital (Brigham and Women’s
Hospital [BWH]) and other clinics at BWH.
Subjects: CLBP patients seeking care at OCC or non-OCC BWH clinics.
Interventions: Integrative or conventional care for CLBP as prescribed by the treating clinician(s).
Outcome measures: Quality-adjusted life years (QALYs) were estimated per treatment approach based on
the SF-12. Cost per QALY gained was evaluated using an incremental cost-effectiveness ratio (ICER). ICERs
based on CLBP-specific effectiveness measures (Roland Disability Questionnaire [RDQ] and bothersomeness
of pain [BOP]) were exploratory outcomes.
Results: Total adjusted annual CLBP-related costs per patient were greater in the OCC versus non-OCC
group ($11,526.73 vs. $6,810.63). Between group differences in QALYs were small and ICER estimate of
cost per QALY gained was high ($436,676). However, unadjusted mean direct costs per patient decreased
over time in the OCC group. Savings in direct costs of $391 (95% confidence interval: -1,078 to 1,861) were
observed in the OCC group for the 6- to 12-month period, driven primarily by reduced medication usage.
ICERs based on adjusted RDQ and BOP group differences showed cost of $2,073 and $4,203 for a one-point
reduction per respective scale.
Conclusions: When adjusted for baseline differences, self-reported costs were higher in the OCC group with
only small effects on QALYs. However, trends toward decreased direct expenditures and medication usage over
time warrant further investigation. Future studies evaluating potential benefits of integrative care models for the
management of CLBP should employ randomized designs, longer observational periods, and explore multiple
metrics of cost-effectiveness.
Keywords: chronic low back pain, integrative medicine, cost-effectiveness, interdisciplinary care
1Osher Center for Integrative Medicine, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA.
2Division of Preventive Medicine, Brigham and Women’s Hospital, Boston, MA.
3Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
4Division of General Medicine and Primary Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA.
5Institute for Complementary and Integrative Medicine, University Hospital Zurich, University of Zurich, Zu¨rich, Switzerland.
6Institute of Social Medicine, Epidemiology, and Health Economics, Charite´–Universita¨tsmedizin Berlin, corporate member
of Freie Universita¨t Berlin, Humboldt-Universita¨t zu Berlin, and the Berlin Institute of Health, Berlin, Germany.
*Both these authors are co-senior authors.
THE JOURNAL OF ALTERNATIVE AND COMPLEMENTARY MEDICINE JACMVolume 25, Supplement 1, 2019, pp. S138–S146ª Mary Ann Liebert, Inc.DOI: 10.1089/acm.2018.0503
S138
Introduction
Chronic low back pain (CLBP) is a highly prevalent,burdensome, and costly health problem in Western in-
dustrialized countries.1–3 Despite considerable investment,
basic and clinical research have not translated into a de-
creased prevalence of CLBP, nor in the development of un-
imodal conventional medical approaches that result in
consistently and markedly improved efficacy.4,5 This has led
many patients to seek complementary and integrative thera-
pies (CIT) for CLBP.6,7 Surveys support that CLBP patients
are among the highest users of CIT,6,8,9 and it is not uncommon
for them to use more than one CIT at the same time, and to
integrate these therapies with conventional care.9–11
The high prevalence of use of CIT for CLBP has catalyzed
clinical research evaluating the safety and effectiveness of these
modalities.12,13 However, less attention has been devoted to
economic evaluation of the cost-effectiveness of CIT for back
pain, and especially to models of care that integrate CIT within
multimodal programs delivered in academic hospital settings.14
This is critical as cost-effectiveness of novel therapeutic strat-
egies, along with safety and clinical effectiveness, are essential
to informing patient and health care policy decisions.
In 2007, the Brigham and Women’s Hospital (BWH) and
Harvard Medical School launched the Osher Clinical Center
(OCC) for Complementary and Integrative Medical Thera-
pies. The clinic is situated within the ambulatory center of
the hospital and can be utilized by any BWH patient without
referral. OCC clinical services include chiropractic, acupunc-
ture, psychiatry, physician-administered integrative medicine
consultations, and multiple mind–body and movement-based
therapies. A unique feature of the clinic is its extensive training
of an integrated multidisciplinary team of clinicians to enhance
interprofessional communication and understanding, and to
optimize shared care.15,16 A primary focus of the clinic is the
treatment of musculoskeletal pain.
We conducted an observational comparative effectiveness
study comparing CLBP patients who received CIT at the OCC
to CLBP patients receiving usual care at other clinics in the same
hospital.17 We found that, at 12 months, CLBP patients who
received CIT at the OCC exhibited significant and clinically
meaningful benefits in functional status and significant, but
clinically small benefits in bothersomeness of pain (BOP).17
In the present article, we report the results of health eco-
nomic analyses comparing these two treatment approaches for
CLBP. First, we compare CLBP-related medical utilization
and expenditures reported over 12 months from a societal
perspective (including direct costs paid by patients and/or re-
imbursed by health insurance and indirect costs due to work
incapacity). Second, we estimate quality-adjusted life years
(QALYs) for each treatment approach based on SF-12 utility
data18 and analyze the cost per QALY gained using an incre-
mental cost-effectiveness ratio (ICER) approach. Finally, in
additional exploratory cost-effectiveness analyses, we estimate
ICERs by using CLBP-specific effectiveness measures, in-
cluding metrics of back pain-related function and BOP.
Materials and Methods
Study design
Details of the background, design, and methods for the
parent study have been previously published.17 In brief, this
observational prospective cohort study was designed to
compare the effectiveness and cost-effectiveness of CLBP
care provided by the OCC team compared with CLBP care
provided in other settings in the same hospital (non-OCC).
All CLBP patients at BWH could choose to receive care at
the OCC, either by their personal choice or as a referral from
a BWH provider. Both the OCC and the non-OCC patients
were treated as per usual care of the treating clinicians. No
treatments were provided by the investigators themselves.
Patients were observed over a 12-month period.
Patients were included if they had a diagnosis of nonspecific
CLBP or had herniated nucleus pulposus or stenosis. CLBP
was defined, as in prior studies, as 3 months or more of CLBP
or 6 months or more of intermittent low back pain.19 Partici-
pants with CLBP related to cancer, fracture, or infection
were excluded. Participants were ‡21 years of age and En-
glish speaking and had to agree to three follow-up assess-
ments by phone over a period of 12 months. All participants
provided written informed consent. The study was approved
by Partners HealthCare Institutional Review Board and was
registered at ClinicalTrials.gov (Identifier NCT01355237).
Medical utilization and cost data
Utilization of medical resources related to CLBP for all
participants was systematically collected with structured
self-report instruments at baseline, and at the 3-, 6-, and 12-
month follow-up interview. Participants documented use of
the therapeutic resources for CLBP over the prior 3 months
(at baseline and the 3- and 6-month interviews) and the prior
6 months (for the 12-month interview) in the following eight
categories: daily activities (e.g., exercise classes, nonmedi-
cal therapies), devices (e.g., support pillows), emergency
room (ER) visits, hospital stays, injections, surgeries, med-
ications, and office visits (to both conventional and CIT
providers). Additionally, data on days of work incapacity
and reduced working hours related to CLBP were collected.
Total costs per patient were estimated by multiplying
reported resource consumption by estimates of mean costs
as follows: ER visits were based on Blue Cross Blue Shield
of Massachusetts (BCBSMA) cost estimates20; hospital
stays were based on the 2012 Agency for Healthcare Re-
search and Quality estimate of average cost per stay21; in-
jections and surgeries were based on American Medical
Association CPT/Medicare payment searches with MD in-
put22; office visits were based on BCBSMA20 (conventional
providers) and expert input and web-derived average Boston-
area costs (CIT providers); medications were based on
costs listed on RED BOOK Online23 (prescription) and
Drugstore.com (over-the-counter, OTC); exercise classes
were based on web-derived average Boston-area costs; and
devices were based on costs listed on Amazon.com.
For estimation of indirect costs, we assumed a value of $30
per hour absent from work as used in other studies.24 The total
cost at a given time period was taken as the sum of costs in each
of the nine categories. Total annual costs were calculated by
summarizing the costs over all time periods. For patients with
data availability of less than the 12-month study duration, the
existing cost data were extrapolated to an annual timeframe.
Utility and clinical outcomes
Our primary parameter for assessing cost-effectiveness
was QALYs based on the SF-12 assessments at baseline,
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and 3, 6, and 12-month follow-ups. Therefore, the SF-12
quality-of-life (QOL) data were converted into SF-6D using
an algorithm developed by Brazier and Roberts.25 For the
SF-6D, preference weights are available, on which the
derivation of health state utilities in our analysis was based.
Minimum requirements for QALY calculation were: (1)
existing SF-12 data at baseline; and (2) at least one existing
SF-12 follow-up dataset. For patients who did not fulfill
these minimum requirements QALYs were not calculated.
Full year QALYs were calculated using the area under the
curve method, which assumes linear changes between lon-
gitudinal utility values.26
Two secondary outcomes were also used for additional
exploratory cost-effectiveness analyses. Back pain-related
functional limitation was assessed with the modified Roland
Disability Questionnaire (RDQ).27 Higher scores (range 0–
23) indicate greater functional limitation. BOP in the past
week was measured on a 0–10 scale (0 indicating ‘‘not at all
bothersome’’; 10 indicating ‘‘extremely bothersome’’).28
For both RDQ and BOP, we defined patients with a clini-
cally meaningful ‡30% improvement as responders.28
Cost-effectiveness
Comparisons of cost-effectiveness between the OCC and
non-OCC groups were assessed using an ICER approach,29
including all patients with existing data on annual costs and
QALYs. ICERs calculate the difference in costs between two
interventions divided by the difference in effects and are typ-
ically employed if both effects and costs are found to be greater
in an intervention group versus control group. The ICER was
calculated as additional U.S. dollars per one effectiveness unit
gained (here: QALY [primary], RDQ point, RDQ responder
[‡30% improvement], BOP point, and BOP responder):
ICER¼ (Total costOCCTotal costnonOCC)=
(EffectsOCCEffectsnonOCC)
For the primary outcome (additional costs per QALY
gained), nonparametric bootstrapping was used to estimate
variability around the arithmetic mean.30 Each of the 1000
bootstrap samples was adjusted for confounding variables
(listed under Statistical Analysis section below). A net-benefit
approach was used to measure the incremental cost-
effectiveness against a threshold value, k, which is often
described as society’s willingness to pay for one extra QALY
gained.31 For a given threshold value k, an intervention would
be considered to be cost effective if its net benefit is greater
than k.32 The net benefit is defined by following relation:
Net benefit¼ (k · [QALYsOCCQALYsnonOCC])
 (Total costOCCTotal costnonOCC)
Bootstrapped cost-effectiveness results were additionally
used to generate cost-effectiveness acceptability curves, which
show the probability of cost-effectiveness for different thresh-
old values with regard to willingness to pay for one extra
QALY.32 A threshold of $50,000 per QALY is often used in
international literature.33 If the ICER is below such a threshold
value, the treatment can be regarded as cost effective. Given the
evidence suggesting that $50,000 per QALY is too low in the
United States,34 a value of $100,000 was defined as the
threshold for cost-effectiveness in the present analysis.
Statistical analyses
Baseline data were reported only descriptively as means
and standard deviations (SDs) or as proportions. Study
outcomes were first analyzed descriptively (e.g., number of
affected patients, means and 95% confidence interval [CI]).
For the main analyses we tested the two-sided null hypoth-
esis, H: mean total costs/effects in OCC group=mean total
costs/effects in non-OCC group across the study period, and
performed an analysis of covariance adjusted for age, sex,
education, marital status, duration of CLBP treatment (in
years) before study start, number of days with pain in the last
180 days, injections for back pain (yes/no), patients’ expec-
tation for improvement, smoking status, body–mass index
(BMI), activity, and baseline value of the outcome (costs at
baseline, utility at baseline). For inferential statistics, SPSSª
was used. Bootstrap analyses were conducted using MS
EXCELª to model cost-effectiveness analyses.
Results
Baseline characteristics
The initial dataset included 309 patients in total. After
exclusion of patients with missing QOL data at baseline
(n = 19) and patients who had not provided QOL data at
follow-up (n = 12), 278 patients (134 OCC, 144 non-OCC)
were included in the present health economic analysis.
The baseline characteristics of study participants before
study onset are summarized in Table 1. The OCC and non-
OCC groups were comparable with regard to age, sex, and
multiple back pain-related characteristics, including time since
start of treatment, use of injections, and number of days with
back pain in the past 180 days. However, patient baseline
characteristics differed relevantly between groups in a number
of other characteristics. Compared with the non-OCC group,
OCC patients were more active, better educated, less likely to
smoke, had lower BMI, were ethnically less diverse, less likely
to be involved in litigation, and reported higher levels of
marriage, employment, physical and mental QOL, expecta-
tions for improvement, and disease-related disability to work.
Finally, differences in total costs between the patient groups
before study onset were relevant with higher costs in the non-
OCC group (OCC: mean $3,723; non-OCC: mean $2,933).
Treatment utilization patterns
As reported previously,17 the two groups were similar in
their frequency of visits to specialists and physical thera-
pists. However, the OCC group had a higher number of
visits to primary care providers and integrative medicine
providers during the course of the study. Regarding treat-
ment received at the OCC, the average number of visits to
the OCC during the study was about 7.3 (SD: 6.7; range: 1–
32). Most patients (about 69%) had a treatment duration of 3
months or less and about 12% of patients had only a single
visit to the OCC during the study timeframe.
Cost outcomes
During the first 3 months of the study, the total unadjusted
direct mean costs per patient were higher for the OCC group
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than the non-OCC group (difference per patient $947 [95%
CI: 500–2,449]). For the period 3–6 months the cost dif-
ference was reduced to $235 (95% CI: -282 to 752), and for
6–12 months there was a direct cost savings of $391 (95%
CI: -1,078 to 1,861) observed. For unadjusted indirect costs
due to reduced work productivity, such a switch was not
observable and these costs were higher in the OCC group
over the complete study duration.
As seen in Table 2, the annual unadjusted total costs over
the complete study period were higher for patients in the
OCC group compared with the non-OCC group (OCC: mean
$9,106 [95% CI: 6,233–11,980], non-OCC: mean $6,283
[95% CI: 4,522–8,043]). Adjusting costs for relevant dif-
ferences in baseline characteristics between groups resulted
in statistically significant higher total costs in the OCC
group compared with the non-OCC group over the complete
study period (OCC: adjusted mean $11,527 [95% CI: 7,766–
15,287]; non-OCC: $6,811 [95% CI: 3,763–9,858]; p=0.024).
When looking into specific cost items, adjusted costs were not
statistically different for medical devices, ER visits, injections,
medications, and indirect costs, but statistically higher in the
OCC group for daily activities, hospitalizations, office visits,
and surgeries.
Effectiveness outcomes
Over 12 months, patients in the OCC group experienced
more unadjusted QALYs compared with the non-OCC
group (OCC: mean 0.6989 [95% CI: 0.6776–0.7202], non-
OCC: mean 0.6205 [95% CI: 0.5975–0.6435]). After ad-
justing for baseline differences, the QALYs during the study
were not statistically different between the groups (OCC:
Table 1. Baseline Characteristics of Participants in the Osher Clinical Center
and Non-Osher Clinical Center Groups Included in Cost-Effectiveness Analysis
OCC (n = 134) Non-OCC (n = 144)
Sociodemographic variables
Sex, n (%)
Male 42 31.3 38 26.4
Female 92 68.7 106 73.6
Current smoker, n (%) 8 6.0 29 20.1
Ethnicity: Hispanic or Latino, n (%) 8 5.6 22 15.3
Employed, n (%) 81 60.4 51 35.4
Litigation, n (%) 13 9.7 30 20.8
Marital status, n (%)
Married or living with partner 83 61.9 47 32.6
Education, n (%)
High school level or below 12 9.0 46 31.9
College or higher education 122 91.0 98 68.1
Physically active, n (%)
No 26 19.4 44 30.6
Yes 93 69.4 94 65.3
Injections ever, n (%)
No 72 53.7 78 54.2
Yes 62 46.3 66 45.8
Age, mean (SD) 50.18 16.65 52.08 15.88
BMI, mean (SD) 26.02 5.48 30.29 7.97
CLBP treatment duration (in years) before study start, mean (SD) 10.81 11.52 11.10 11.09
Expectation for improvement, mean (SD) 6.02 2.63 2.92 3.10
Days with pain in last 180 days, mean (SD) 144.08 43.67 153.52 46.06
Physical QOL component score, mean (SD) 45.69 11.03 39.41 9.78
Mental QOL component score, mean (SD) 51.85 8.86 46.45 11.81
Utility at baseline, mean (SD) 0.64 0.14 0.58 0.13
Number work incapacity days, mean (SD) 6.13 18.51 2.45 11.94
Costs before study onset
Daily activities, mean (SD) $182.20 $627.20 $90.42 $398.10
Devices, mean (SD) $9.24 $28.94 $11.96 $29.95
ER visits, mean (SD) $47.76 $186.17 $257.78 $728.22
Hospitalizations, mean (SD) $34.49 $399.30 $48.15 $331.24
Injections, mean (SD) $28.39 $63.69 $51.98 $219.88
Medication, mean (SD) $471.99 $2,021.58 $762.21 $2,386.25
Office visits, mean (SD) $813.84 $949.22 $779.64 $1,094.54
Surgeries, mean (SD) $0.00 $0.00 $18.43 $134.54
Indirect costs, mean (SD) $2,135.14 $6,166.35 $912.90 $3,950.74
Total costs, mean (SD) $3,723.05 $6,732.21 $2,933.46 $3,950.74
BMI, body–mass index; CLBP, chronic low back pain; ER, emergency room; OCC, Osher Clinical Center; QOL, quality of life; SD,
standard deviation.
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adjusted mean 0.6420 [95% CI: 0.6204–0.6635]; non-OCC:
adjusted mean 0.6312 [95% CI: 0.6135–0.6489]; p = 0.362).
There was a greater increase in back function in the OCC
group compared with the non-OCC group (adjusted differences
in RDQ scale OCC: -1.726 [95% CI: -2.973 to -0.480] and
non-OCC +0.548 points [95% CI: -0.506 to 1.603]; resulting
in a clinically meaningful adjusted group difference of 2.275
points [95% CI: 3.630 to 0.919; p=0.001]). The proportion of
RDQ responders (‡30% improvement) was 20.3% in the OCC
group and 10.6% in the non-OCC group (p=0.011). Results
were similar for the BOP scale (OCC: -1.536 points [95% CI:
-2.220 to -0.852] and non-OCC: -0.414 points [95% CI:
-0.969 to 0.141]; adjusted group difference of 1.122 points
[95% CI: 1.865 to 0.379; p=0.003]). The proportion of BOP
responders was 39.8% in the OCC group and 20.9% in non-
OCC group (p=0.001).
Cost-effectiveness
As shown above, the modestly greater improvement in
QALYs in the OCC treatment compared with the non-OCC
treatment (adjusted models) was associated with higher
costs. The primary ICER was $436,676 per QALY gained in
the OCC group. A cost-effectiveness plane of this estimate
and its uncertainty, based on bootstrapping (1000 estimates),
is shown in Figure 1.
Nearly all bootstrap samples are located in the upper
quadrants, indicating that cost savings associated with
the intervention are unlikely. Three quarters (76.3%) of the
Table 2. Unadjusted and Adjusted Annual Costs and Resource Consumption per Patient
Cost item
OCC Non-OCC
Na
Mean (95% CI)
Na
Mean (95% CI)
p-Value for adjusted meanb Adjusted mean (95% CI) Adjusted mean (95% CI)
Daily activities 60 $486.63 (294.16 to 679.10) 25 $77.08 (32.02 to 122.15)
p = 0.003 $419.42 (181.26 to 657.58) $20.09 (-174.14 to 214.31)
Devices 60 $65.73 (7.80 to 123.67) 53 $42.53 (-1.28 to 86.35)
p = 0.216 $100.44 (33.45 to 167.44) $54.55 (0.08 to 109.01)
ER visits 7 $47.76 (10.73 to 84.80) 33 $433.33 (271.08 to 595.59)
p = 0.428 $418.12 (245.84 to 590.41) $494.06 (352.44 to 635.68)
Hospitalizations 12 $1,234.89 (-151.09 to 2,620.87) 7 $224.69 (48.47 to 400.91)
p = 0.033 $2,108.07 (432.47 to 3,783.68) $119.89 (-1,236.95 to 1,476.72)
Injections 36 $101.95 (49.61 to 154.29) 36 $249.25 (116.44 to 382.07)
p = 0.270 $177.88 (31.52 to 324.25) $267.16 (148.17 to 386.14)
Medications 124 $970.31 (578.89 to 1,361.73) 134 $2,553.99 (1,160.64 to 3,947.33)
p = 0.634 $2,189.38 (387.07 to 3,979.69) $2,656.21 (1,199.04 to 4,113.38)
Office visits 127 $2,430.21 (1,954.45 to 2,905.96) 114 $1,271.39 (988.00 to 1,554.78)
p < 0.001 $2,904.28 (2,294.86 to 3,516.69) $1,279.30 (784.56 to 1,774.04)
Surgeries 12 $165.76 (73.43 to 258.10) 5 $27.89 (-4.31 to 60.08)
p = 0.006 $246.38 (134.61 to 358.14) $74.51 (-15.89 to 164.91)
Indirect costs 42 $3,603.09 (1,520.40 to 5,685.78) 25 $1,402.46 (551.35 to 2,253.57)
p = 0.433 $2,851.41 (338.54 to 5,364.27) $1,761.72 (-262.16 to 3,785.61)
Total costs 134 $9,106.33 (6,232.64 to 11,980.02) 144 $6,282.62 (4,521.82 to 8,043.42)
p = 0.024 $11,526.73 (7,766.14 to 15,287.31) $6,810.63 (3,763.15 to 9,858.11)
Annual resource consumption
Number ER visits 7 0.07 (0.02 to 0.13) 33 0.68 (0.42 to 0.93)
p = 0.428 0.65 (0.38 to 0.92) 0.77 (0.55 to 0.99)
No. of hospitalizations 12 0.13 (0.05 to 0.20) 7 0.05 (0.01 to 0.08)
p = 0.007 0.25 (0.15 to 0.35) 0.10 (0.01 to 0.18)
Days of hospitalization 12 0.53 (-0.05 to 1.13) 7 0.10 (0.02 to 0.17)
p = 0.033 0.91 (0.19 to 1.64) 0.05 (-0.54 to 0.64)
No. of different drugs 124 4.77 (4.15 to 5.39) 134 5.57 (4.94 to6.20)
p = 0.350 6.11 (5.21 to 7.01) 5.65 (4.92 to 6.38)
No. of office visits 127 22.80 (18.35 to 27.26) 114 10.97 (8.31 to 13.64)
p £ 0.001 26.87 (21.11 to 32.62) 11.22 (6.54 to 15.90)
Number work incapacity days 30 7.95 (2.22 to 13.67) 21 3.34 (0.39 to 6.29)
p = 0.615 7.77 (0.52 to 15.01) 5.75 (-0.09 to 11.60)
aPatients actually being affected by the item, mean values are referring to the total n by group.
bAdjusted for: age, sex, education, marital status, time since LBP treatment start, number of days with pain in the last 180 days, injections
for back pain (yes/no), patients’ expectation for improvement, smoking status, BMI, activity, baseline value of the outcome.
95% CI, 95% confidence interval; BMI, body-mass index; ER, emergency room; LBP, low back pain; OCC, Osher Clinical Center.
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bootstrapped QALY differences are located in the upper right
quadrant indicating a better effectiveness at higher costs in
the OCC group. The remaining bootstrap samples show lower
QALYs compared with the non-OCC group. When using the
net-benefit approach to measure the cost-effectiveness prob-
ability against a range of threshold values for willingness-to-
pay for one extra QALY gained (Fig. 2) the cost-effectiveness
probability reaches 9.8% assuming the a priori-defined
willingness-to-pay of $100,000 per QALY gained.
Exploratory analyses for ICERs based on adjusted RDQ
group differences (in favor of OCC) showed that the cost for
a one-point reduction on the RDQ was $2,073 and the cost
per additional RDQ responder was $48,620. Parallel explor-
atory ICERs for adjusted BOP scores (in favor of OCC) in-
dicated the cost for a one-point reduction in BOP was $4,203,
and the cost per additional BOP responder was $24.953.
Discussion
This observational study characterized back pain-related
costs and cost-effectiveness for care delivered at a multi-
modal integrative care clinic based in a tertiary care hospital
(OCC), as compared with care delivered in the same hos-
pital but outside the OCC. Over a 12-month period, analyses
adjusted for important baseline differences indicate statis-
tically significant and greater CLBP-related total costs per
patient in the OCC group compared with the non-OCC
group. In contrast, QALYs were only marginally improved
in the OCC group. Consequently, the ICER estimate of cost
per QALY gained (our primary cost-effectiveness outcome)
was high ($436,676) and not below the a priori-defined
threshold for cost-effectiveness. However, the two primary
back pain-specific clinical outcomes evaluated, RDQ and
BOP (coprimary outcomes in our clinical study),17 showed
clinically meaningful and statistically greater improvements
at 12 months in the OCC versus the non-OCC group. ICERs
based on these outcomes (exploratory analyses) provide
alternative cost-effectiveness estimates.
Between-study comparisons of cost-effectiveness are
difficult due to variability in populations studied (e.g., acute
vs. CLBP), therapeutic exposures (types and doses), costs
considered (e.g., general medical vs. back pain specific), and
time frames of observation. Nevertheless, our finding of lack of
cost-effectiveness based on QALYs for the model of integrated
care delivered at the OCC contrasts with other studies, which
have reported that adding individual or multiple integrative
care therapies (e.g., spinal manipulation, acupuncture, yoga,
cognitive behavioral therapy, mindfulness-based stress reduc-
tion) to usual routine care can be cost effective.35–40 For ex-
ample, the UK BEAM trial reported that a combination of spinal
manipulation and exercise had a greater impact on QALYs and
was cost effective compared with usual care.36 However, this
study targeted both subacute and CLBP patients and included
general health care costs in addition to back pain-specific costs.
More recently, the ATEAM study also reported that the use
of certain combinations of integrative therapies (Alexander
technique) with exercise were clinically more effective than
usual care, with ICERs for the best therapy combination
FIG. 1. Cost-effectiveness plane. Cost-effectiveness of OCC versus non-OCC treatment of chronic low-back pain based
on bootstrapping (1000 estimates). OCC, Osher Clinical Center; QALYs, quality-adjusted life years.
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estimated to be £5,332 per QALY gained.37 Of note, QALYs
gained in this study were as high as 0.065, which contrasts
with the smaller between-group difference in QALY of 0.011
observed in our study. Paralleling our findings, Kominski
et al.41 reported that the addition of chiropractic care, with or
without ancillary physical modalities, was associated with
higher medical costs and was not cost-effective.
A closer look at both costs and clinical outcomes, and
especially their changes over 12 months, reveals a noteworthy
trend. When averaged over the 12-month period, CLBP-
related costs were $4,716 higher in the OCC versus the non-
OCC group. The largest contributors to between-group total
cost differences, in order of magnitude and all with higher
costs in OCC were, office visits ($1,625), indirect costs
($1,090), hospital visits (non-ER) ($871), daily activities
($394), and surgeries ($172). However, when only looking at
direct costs, the magnitude of between-group difference in
total expenditures decreased over time, from $947 to $235
per patient at 3 and 6 months, respectively, and then showed a
mean cost savings of $391 in the OCC group at 12 months.
A closer look at patterns of medical expenditures over time
reveals that the observed savings in direct costs in the OCC
during later observational periods were largely driven by re-
duced usage of CLBP-related medications (data not shown).
The number of OCC patients that reported taking CLBP med-
ications at 3, 6, and 12 months was 126, 105, and 90, respec-
tively. In contrast, the number of non-OCC patients that reported
taking CLBP medications did not decline as dramatically be-
tween 3, 6, and 12 months, and was 138, 120, 119, respectively.
This observation warrants further investigation in future trials.
In addition to potentially impacting cost savings, the
observed reduced dependence on pain medications in the
OCC suggests that integrative models of CLBP care may
contribute to the reduction of overreliance on potentially
dangerous and addictive medications, known to have sig-
nificant implications to both individuals and society.42–44
Magnitudes of between-group differences in QALYs were
small and did not differ markedly over the 12 months. In
contrast, the magnitude of between-group differences in back
pain-related disability in favor of OCC was more marked.
Adjusted between-group differences in RDQ were 0.30, 0.95,
and 2.08 at 3-, 6-, and 12-month assessments, respectively.17
It is noteworthy that most patients in the OCC group were
treated at the OCC only during the first 3 months of the study,
suggesting a potential delayed impact on disability. One inter-
pretation of these findings is that sustained and longer-term
improvements in RDQ in the OCC group contributed to the
reductions in medical spending observed only during the 6- to
12-month observation period. These longer-term clinical ef-
fects may be attributable to the explicit emphasis on self-care
that was a primary focus of the team-based training at the
OCC.15,16 Future studies of the OCC should include an extended
(e.g., 2-year) observation period to better evaluate potential
longer-term impacts on effectiveness and cost-effectiveness.
The noteworthy trend in improvement in RDQ over time, and
its association with decreased medical spending also led us to
explore alternative metrics of cost-effectiveness based on dis-
ability, as has been done in prior back pain studies.37,45,46 ICERs
based on adjusted RDQ group differences showed that cost for a
one-point reduction in the RDQ was $2,073 and cost per
FIG. 2. Probability of cost-effectiveness against different willingness-to-pay threshold values. QALYs, quality-adjusted
life years.
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additional RDQ responder was $48,620. Because there is little
consensus on cost-effectiveness thresholds for utility values
other than QALYs, these findings are difficult to interpret.
However, for comparison, Hollinghurst et al. estimated that
incremental costs (including both direct and indirect) for a point
reduction in RDQ were £448, £113, and £61 for massage ther-
apy, Alexander lessons, and exercise, when these were com-
pared with usual care in patients with CLBP.37 Other studies,
including ICERs based on alternative metrics of disability or
pain scales suggest that estimates of cost-effectiveness based on
measures other than QALY can provide valuable and comple-
mentary data for assessing the clinical and economic evidence
base for alternative LBP treatment strategies.45,46
Our study has a number of limitations. While our analyses
controlled for important known baseline differences between
the OCC- and non-OCC-treated groups, it is possible that
other residual confounders, unknown or unmeasured, could
have contributed to our observed group differences in this
observational study. We were unable to obtain information
about referral patterns to the OCC and other non-OCC clinics;
therefore, we cannot rule out the possibility of selection bias.
Baseline differences in sociodemographic factors, and in
particular, with wealthier and more educated patients choosing
care at the OCC, could have influenced patterns of medical
spending that were not fully accounted for in our modeling.
With these limitations in mind, however, our findings suggest
modest improvements in functional status and BOP, and
trends toward savings in direct cost during latter periods of
observation, supporting the potential value of evaluating
multimodal integrative models for the treatment of CLBP in
more definitive randomized controlled trials.
In addition, this study focused on the effectiveness of
care delivered by a multimodal integrative care clinic in a
single academic center hospital. Large-scale multisite ran-
domized trials would be needed to make broader general-
izations regarding the effectiveness and cost-effectiveness
of multimodal integrative approaches to CLBP. Toward this
end, two complementary approaches could be used.
First, and more pragmatic, would be to replicate at a larger
scale the strategy employed in this study. CLBP patients at
multiple academic medical centers would be randomly assigned
to receive care at an integrative medicine clinic or through
conventional care within the same institution. The inclusion of
multiple integrative medical clinics, each with their unique
model of delivery, would afford good generalization regarding
the benefits of integrative medicine approaches for CLBP.
Alternatively, and less pragmatic, would be to evaluate
the impact of specific subsets of combinations of therapies
most commonly used at integrative medicine centers. In the
case of the OCC, this would be chiropractic plus acupunc-
ture, or chiropractic plus mind–body training.17 Findings
from this approach would result in more focused recom-
mendations regarding the use of multimodal approaches in
the treatment of CLBP, and also lay a better foundation for
exploring mechanisms underlying observed synergistic
clinical and economic benefits.
Conclusions
Patients who utilize integrative care in an academic
hospital setting differ substantially from those who utilize
conventional treatments. When baseline sociodemographic
and back pain-related differences are accounted for, self-
reported costs were higher in the integrative care group with
no apparent effect on QALYs, despite meaningful im-
provements in CLBP-related disability and BOP at 12
months. Future studies evaluating potential benefits of in-
tegrative care models for the management of CLBP should
employ randomized clinical designs, longer observational
periods, and explore multiple metrics of cost-effectiveness.
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